CAMBRIDGE, Mass.--(BUSINESS WIRE)--Leading stem cell therapeutic and regenerative medicine company, AuxoCell Laboratories, Inc., today announced an agreement with CordVida, a Brazilian stem cell cryopreservation company, which will allow CordVida to expand its services. Families who select CordVida to store umbilical cord blood will now have the opportunity to bank stem cells from an additional source – cord tissue. With this agreement, AuxoCell broadens its international reach to South America.
“At AuxoCell, we are pleased by the opportunity to provide this groundbreaking technology to families around the globe,” said Rouzbeh R. Taghizadeh, PhD, Chief Scientific Officer of AuxoCell Laboratories, Inc. “CordVida is Brazil’s premier cord blood bank and adheres to the highest quality standards. It is for that reason that we have selected them as our exclusive partner in Brazil.”
Cord tissue has an abundant source of mesenchymal stem cells (MSCs). Currently, there is a significant amount of research underway focused on mesenchymal stem cells extracted from cord tissue. MSCs are rapidly becoming the leading stem cell in regenerative medicine studies, and MSCs from a variety of sources are in use in over 150 clinical trials. The AuxoCell cord tissue technology represents the gold standard in the industry, as its technology prepares stem cells that are ready for immediate use, if needed.
“CordVida is excited to be the first company in Brazil to offer storage of multiple kinds of stem cells,” says Roberto Waddington, CEO for CordVida. “Considering the enormous therapeutic prospects of cord tissue derived MSCs, our clients in the future will now rely on a much wider array of potential therapeutic applications. We are proud that AuxoCell selected CordVida as its exclusive technology partner for all of Brazil.”
Banking umbilical cord tissue stem cells offers clients a chance to reap the benefits of research that is being conducted on MSCs. Additionally, AuxoCell’s own studies have shown that a combination of cord tissue mesenchymal stem cells derived using AuxoCell’s validated processing SOPs and hematapoietic stem cells (HSCs) from the cord blood enhances the engraftment of the cord blood HSCs.
About AuxoCell
AuxoCell Laboratories, Inc. (AuxoCell) is a leading stem cell therapeutic and regenerative medicine company located in Massachusetts. AuxoCell's primary research focus is to develop the enormous therapeutic potential of the primitive stem cells found in the Wharton's Jelly of the human umbilical cord. With exclusive patent rights and proprietary processing protocols, AuxoCell is uniquely situated to offer the very best in cord tissue stem cell banking. Through strategic partnerships with both private and public cord blood banks, stem cell centers, and research laboratories around the world, AuxoCell strives every day to bring novel stem cell therapies from the bench to the bedside. Additional information is available through HYPERLINK www.auxocell.com or at (617) 610-9000.
About CordVida
Founded in 2004, CordVida is the premier stem cell cryopreservation company in Brazil with 10.000 umbilical cord blood units stored. It is the cord blood bank of choice for key doctors in Brazil. Committed to the highest global quality standards, CordVida has been AABB accredited since 2008. Half of the transplants made in Brazil using private cord blood units have been made with units stored in CordVida.